Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Clin Apher ; 16(2): 74-81, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11746532

RESUMEN

We attempted to determine whether various cytokine levels in the serum and synovial fluid (SF) of rheumatoid arthritis (RA) patients are influenced by the performance of filtration leukocytapheresis (LCP). The filtration LCP procedure that used a Cellsorba column (LCP group: n=22; responder subgroup: n=17, non-responder subgroup: n=5) or sham apheresis (control group; n=7) was repeated three times at 1-week intervals. Serum (LCP group, n=22; control group, n=7) and SF (LCP group, n=6; control group, n=3) samples were collected before and after LCP. Levels of tumor necrosis factor alpha (TNFalpha), interleukins (IL-1 beta, IL-2, IL-6, IL-8, IL-10, and IL-15), granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), RANTES were measured by an enzyme-linked immunosorbent assay. Serum TNF alpha, IL-15, and RANTES were significantly reduced only in the LCP group. Serum IL-10 significantly increased only in the LCP group. In the LCP subgroup, serum IL-15, GM-CSF, and RANTES levels were reduced significantly, while serum IL-10 levels increased significantly only in the responder group after treatment. Serum TNF alpha levels were reduced significantly in both subgroups. Changes in serum IL-10 correlated positively with the improvement of patient's assessment of pain and global severity, and physician's assessment of global severity. These results indicate that the removal of leukocytes from the peripheral blood of RA patients provokes dynamic changes in some cytokine levels in the serum and/or synovial fluid. These changes may explain some of the mechanisms by which the articular symptoms are improved by filtration LCP.


Asunto(s)
Artritis Reumatoide/terapia , Enfermedades Autoinmunes/terapia , Citocinas/análisis , Leucaféresis , Líquido Sinovial/química , Adulto , Artritis Reumatoide/sangre , Enfermedades Autoinmunes/sangre , Quimiocina CCL2/sangre , Quimiocina CCL5/sangre , Citocinas/sangre , Método Doble Ciego , Femenino , Filtración , Factor Estimulante de Colonias de Granulocitos y Macrófagos/sangre , Humanos , Interleucinas/sangre , Leucaféresis/instrumentación , Leucaféresis/métodos , Factor Estimulante de Colonias de Macrófagos/sangre , Masculino , Persona de Mediana Edad , Células TH1/metabolismo , Células Th2/metabolismo , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/análisis
2.
Intern Med ; 40(10): 1055-8, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11688834

RESUMEN

A 29-year-old man was admitted because of fever, arthralgia and swelling of the cervical lymph nodes. A diagnosis of histiocytic necrotizing lymphadenitis (HNL) was made based on the findings of a lymph node biopsy. At first, piperacillin sodium (PIPC) was started, but a spiking fever persisted. We therefore changed the PIPC treatment to minocycline. On the following day, his clinical and laboratory findings were dramatically improved. After administering minocycline for 10 days, the HNL symptoms completely disappeared. He has been in good health for 3 years since undergoing treatment. This case strongly indicates that minocycline-sensitive microorganism(s) may be related, at least in part, to the etiology of HNL.


Asunto(s)
Antibacterianos/uso terapéutico , Linfadenitis Necrotizante Histiocítica/tratamiento farmacológico , Minociclina/uso terapéutico , Adulto , Linfadenitis Necrotizante Histiocítica/patología , Humanos , Masculino , Inducción de Remisión , Factores de Tiempo
3.
Intern Med ; 40(8): 829-32, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11518137

RESUMEN

We present here a case of Sjögren's syndrome (SjS) with osteomalacia based on renal tubular acidosis type 1 (RTA-1). A 53-year-old woman, diagnosed as having rheumatoid arthritis (RA) at the age of 33, was admitted to our hospital because of sicca complex, fatigability and worsening general aching. The activity of RA had been low, but it was complicated by SjS, RTA-1 and remarkable osteomalacia. Acidosis was corrected by alkali supplement therapy. By treatment with a regimen consisting of alfacalcidol, calcium L-aspartate, elcatonin and ipriflavone, her bone mineral density (BMD) was remarkably improved within months and the generalized aching gradually diminished.


Asunto(s)
Acidosis Tubular Renal/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Calcitonina/análogos & derivados , Osteomalacia/diagnóstico , Osteomalacia/etiología , Síndrome de Sjögren/tratamiento farmacológico , Acidosis Tubular Renal/etiología , Adyuvantes Inmunológicos/uso terapéutico , Analgésicos/uso terapéutico , Artritis Reumatoide/complicaciones , Densidad Ósea , Calcitonina/uso terapéutico , Compuestos de Calcio/uso terapéutico , Femenino , Humanos , Hidroxicolecalciferoles/uso terapéutico , Isoflavonas/uso terapéutico , Persona de Mediana Edad , Síndrome de Sjögren/complicaciones , Resultado del Tratamiento
4.
Biochem Cell Biol ; 79(2): 177-82, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11310565

RESUMEN

Lipid microspheres (LM), currently in clinical use as drug carriers, mainly consist of soybean oil as a core and lecithin as a surfactant. The purpose of our study wass to determine whether or not LM incorporation is receptor-mediated. U937 cells resuspended in a serum-free medium abundantly took up unmodulated LM. A binding study showed that U937 cells had a single binding site for LM (410 sites/cell at 24 degrees C; 100 sites/cell at 4 degrees C). Inhibition assays revealed that lecithin liposome, lysophosphatidylcholines, activated alpha2-macroglobulin, and HDL did not affect the binding of LM to U937 cells. VLDL strongly, and LDL and AcLDL moderately, inhibited the binding of LM to U937 cells. Ligand blotting analysis revealed that unmodulated LM in an apoprotein-free buffer directly bound to a 40 kDa protein in the cell membrane fraction. These results suggest that LM that is not modulated by any protein is incorporated by specific cells via receptor-mediated processes.


Asunto(s)
Portadores de Fármacos/farmacocinética , Lípidos/farmacocinética , Receptores de Lipoproteína/metabolismo , Células U937/metabolismo , Sitios de Unión/efectos de los fármacos , Sitios de Unión/fisiología , Unión Competitiva , Humanos , Ligandos , Lípidos/antagonistas & inhibidores , Lípidos/química , Lipoproteínas LDL/metabolismo , Lipoproteínas LDL/farmacología , Lipoproteínas VLDL/metabolismo , Lipoproteínas VLDL/farmacología , Microesferas
6.
J Clin Apher ; 15(4): 262-5, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11124695

RESUMEN

Anti-annexin V (Anx V) antibodies are detected in SLE patients and patients with habitual fetal loss or preeclampsia. Several case reports have indicated that recurrent abortion based on antiphospholipid syndrome (APS) could be successfully treated with immunoadsorption by using dextran sulfate (DS) columns. The purpose of this study is to clarify whether or not anti-Anx V is also adsorbed by DS-bound cellulose beads. Sera from anti-Anx V-positive patients were mixed with DS-bound cellulose beads in vitro, and the titers of anti-Anx V were measured both before and after incubation. The anti-Anx V titers significantly decreased after incubation. The Anx V also bound to bovine serum albumin-conjugated DS immobilized on microtiter plates. The results of the present study lend support to the basic rationale for immunoadsorption therapy using DS columns in the treatment of habitual abortion closely associated with anti-Anx V antibodies.


Asunto(s)
Anexina A5/inmunología , Síndrome Antifosfolípido/terapia , Autoanticuerpos/aislamiento & purificación , Técnicas de Inmunoadsorción , Adolescente , Adulto , Celulosa , Sulfato de Dextran , Femenino , Humanos , Masculino , Persona de Mediana Edad
7.
Mod Rheumatol ; 10(1): 19-23, 2000 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24383529

RESUMEN

Abstract The presence of antiphospholipid antibodies and/or lupus anticoagulant (LA) increase the risk of thrombosis, while the onset of thrombosis is usually sudden. The objective of this study was to determine whether or not some episodes triggered thrombotic events in patients possessing antiphospholipid antibodies. Fifteen patients who presented with thrombosis (primary antiphospholipid syndrome (APS), six cases; secondary APS, nine cases) were retrospectively examined to discover whether or not any specific episodes occurred prior to a total of 21 thrombotic events. In five events occurring in five female patients, specific episodes were identified, including the wearing of tight underwear, dehydration due to fever and standing in hot and humid weather, fever following the extraction of a carious tooth, steroid pulse therapy, toxemia during pregnancy, and intrauterine fetal death. To prevent the occurrence of thrombosis in patients possessing antiphospholipid antibodies, it appears to be important to avoid such triggering episodes and also to reduce the risk factors for thrombosis.

8.
Ther Apher ; 3(1): 75-80, 1999 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10079810

RESUMEN

The purpose of this study was to clarify the basic adsorption selectivity characteristics of dextran sulfate (DS) columns (Selesorb, Kaneka Corporation, Osaka, Japan). Recovery rates of blood chemical components, hormones, coagulation factors, and antinuclear antibodies (anti-SS-A, SS-B, Sm, Scl-70, and RNP antibody) in vitro were assessed by mixing normal volunteers' or patients' sera with DS bound cellulose beads. For tested blood chemical components other than triglyceride and total cholesterol, the recovery rate was not changed significantly by incubation. No significant changes in hormone levels resulted from incubation. Among coagulation factors, the activities of antithrombin III, plasminogen, and factors V, VIII, IX, XI, and XII were significantly reduced by incubation. Among antinuclear antibodies tested, anti-SS-A and anti-RNP were absorbed to some extent, but not anti-SS-B, Sm, or Scl-70 antibodies. Taking into account these characteristics, apheresis therapy using a DS column should be performed.


Asunto(s)
Autoanticuerpos/aislamiento & purificación , ADN/inmunología , Sulfato de Dextran , Técnicas de Inmunoadsorción , Adsorción , Humanos
9.
Arthritis Rheum ; 42(3): 431-7, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10088764

RESUMEN

OBJECTIVE: To determine the efficacy and safety of filtration leukocytapheresis (LCP) for the treatment of rheumatoid arthritis (RA). METHODS: Twenty-five patients with drug-resistant RA were randomly assigned to undergo filtration LCP and 7 to undergo sham apheresis (control group) in a randomized, double-blind, placebo-controlled study. Three apheresis procedures were performed, with 1-week intervals between procedures. The efficacy of filtration LCP was evaluated according to the American College of Rheumatology definition of improvement in RA. Medications for each patient were unchanged for at least 6 months prior to enrollment and throughout the study. RESULTS: Tender joint counts, swollen joint counts, patient assessment of pain and global severity, physician assessment of global severity, and Health Assessment Questionnaire Disability Index were significantly improved in the LCP group compared with the control group (P < 0.05 for patient assessment of pain; P < 0.01 for all others). Seventy-nine percent of the patients in the LCP group exhibited significant overall improvement, while none of the patients in the control group were improved (P < 0.001). CONCLUSION: The results indicate that filtration LCP is an effective and well-tolerated treatment for patients with drug-resistant RA.


Asunto(s)
Artritis Reumatoide/inmunología , Artritis Reumatoide/terapia , Leucaféresis , Adulto , Artralgia/etiología , Artralgia/inmunología , Artralgia/terapia , Artritis Reumatoide/complicaciones , Método Doble Ciego , Resistencia a Medicamentos , Femenino , Humanos , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Placebos
10.
Ann Rheum Dis ; 57(10): 602-5, 1998 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9893571

RESUMEN

OBJECTIVES: To investigate the regulatory roles of interleukin 1 beta (IL1 beta), tumour necrosis factor alpha (TNF alpha), interferon gamma (IFN gamma) or transforming growth factor beta 1 (TGF beta 1) on hyaluronan (HA) synthesis by human fibroblastic synovial lining cells. METHODS: Concentrations of HA in culture supernatants of fibroblastic synovial lining cell line (RAMAK-1 cell line) with or without stimulation by IL1 beta, TNF alpha, IFN gamma or TGF beta 1 were measured by sandwich binding protein assay. Levels of HA synthase mRNA of the cells with or without stimulation were detected by reverse transcribed polymerase chain reaction. Molecular weights of HA in the culture supernatants of the cells with or without stimulation were measured using high performance gel permeation liquid chromatography. RESULTS: HA synthesis by the cells was not significantly augmented by TNF alpha or by IFN gamma. It was significantly stimulated by IL1 beta but inhibited by TGF beta 1. Molecular weights of HA in the culture supernatants of the cells were unchanged by stimulation with TNF alpha. They were remarkably increased by stimulation with IL1 beta and IFN gamma, but reduced with TGF beta 1. CONCLUSION: IL 1 beta is an up regulator of HA synthesis, while TGF beta 1 is a down regulator. HA production in the synovial lining cells of inflamed joints (for example, rheumatoid arthritis) might be regulated by the balance of these cytokines.


Asunto(s)
Artritis Reumatoide/metabolismo , Citocinas/farmacología , Glicosiltransferasas , Ácido Hialurónico/biosíntesis , Proteínas de la Membrana , Membrana Sinovial/metabolismo , Transferasas , Proteínas de Xenopus , Técnicas de Cultivo de Célula , Línea Celular , Relación Dosis-Respuesta a Droga , Fibroblastos/metabolismo , Expresión Génica , Glucuronosiltransferasa/genética , Humanos , Hialuronano Sintasas , Ácido Hialurónico/química , Interleucina-1/farmacología , Peso Molecular , ARN Mensajero/genética , Factor de Crecimiento Transformador beta/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA